Liver cancer, which includes hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally, responsible for more than 700,000 deaths worldwide each year.
Although this cancer type is less common in the United States, the American Cancer Society estimates that for 2021,42,230 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed and about 30,230 individuals will die of these cancers nationwide.
In the U.S., incidence rates of liver cancer in young adults have started to decline; however, the incidence of liver cancer in adults has more than tripled over the last 40 years. Nationally, death rates from liver cancer have increased by about one percent each year for women and have stabilized for men.
Effective prevention and treatment strategies for liver cancer remain an area of need. Active research in liver cancer is underway as several new therapies, including multikinase inhibitors and checkpoint inhibitor immunotherapy, have been approved to treat liver cancer, with more showing promise.
ACCC identified effective practices in multidisciplinary care hepatocellular carcinoma (HCC) and is providing peer-to-peer learning and resources for effective care coordination and communication.
Results from cancer program case studies illustrate the complexities of the disease and care planning and reinforce the value of a multidisciplinary approach. Learn practical tips for improving communication and care coordination across the multidisciplinary cancer care team and with patients.
Access ACCC’s Liver Cancer Heatmap to better understand the current incidence, mortality rates, and health disparities that exist across the United States.
Explore this curated resource bank to learn more about screening and treatment guidelines, training opportunities, patient education, and clinical trials for HCC.
Akce Gives Insights on How Immunotherapy is Changing the HCC Treatment Landscape -
via Targeted Oncology
June 28, 2021